Innovative Therapies and Nanomedicine Applications for the Treatment of Alzheimer’s Disease: A State-of-the-Art (2017–2020)

References

• Yiannopoulou KG, Papageorgiou SG. Current and future treatments in alzheimer disease: an update. J Cent Nerv Syst Dis. 2020;12:1179573520907397. doi:10.1177/117957352090739732165850
   PubMed Web of Science ®Google Scholar
• Faustino C, Rijo P, Reis CP. Nanotechnological strategies for nerve growth factor delivery: therapeutic implications in Alzheimer’s disease. Pharmacol Res. 2017;120:68–87. doi:10.1016/j.phrs.2017.03.02028351757
   PubMed Web of Science ®Google Scholar
• Tiwari S, Atluri V, Kaushik A, Yndart A, Nair M. Alzheimer’s disease: pathogenesis, diagnostics, and therapeutics. Int J Nanomedicine. 2019;14:5541–5554. doi:10.2147/IJN.S20049031410002
   PubMed Web of Science ®Google Scholar
• Ahmad J, Akhter S, Rizwanullah M, et al. Nanotechnology based theranostic approaches in Alzheimer’s Disease management: current status and future perspective. Curr Alzheimer Res. 2017;14(11):1164–1181. doi:10.2174/156720501466617050812103128482786
   PubMed Web of Science ®Google Scholar
• Martín-Rapun R, De Matteis L, Ambrosone A, Garcia-Embid S, Gutierrez L, de la Fuente JM. Targeted nanoparticles for the Treatment of Alzheimer’s Disease. Curr Pharm Des. 2017;23(13):1927–1952. doi:10.2174/138161282266616122615101128025949
   PubMed Web of Science ®Google Scholar
• Moreno S, Cerù MP. In search for novel strategies towards neuroprotection and neuroregeneration: is PPARα a promising therapeutic target? Neural Regen Res. 2015;10(9):1409–1412. doi:10.4103/1673-5374.16531326604898
   PubMed Web of Science ®Google Scholar
• Karran E, De Strooper B. The amyloid cascade hypothesis: are we poised for success or failure? J Neurochem. 2016;139(Suppl 2):237–252. doi:10.1111/jnc.1363227255958
   PubMedGoogle Scholar
• Uddin MS, Kabir MT, Niaz K, et al. Molecular Insight into the therapeutic promise of flavonoids against Alzheimer’s Disease. Molecules. 2020;25:6. doi:10.3390/molecules25061267
   Web of Science ®Google Scholar
• Furtado D, Björnmalm M, Ayton S, Bush AI, Kempe K, Caruso F. Overcoming the blood-brain barrier: the role of nanomaterials in treating Neurological Diseases. Adv Mater. 2018;30(46):e1801362.30066406
   PubMed Web of Science ®Google Scholar
• Harilal S, Jose J, Parambi DGT, et al. Advancements in nanotherapeutics for Alzheimer’s disease: current perspectives. J Pharm Pharmacol. 2019;71(9):1370–1383. doi:10.1111/jphp.1313231304982
   PubMed Web of Science ®Google Scholar
• Kevadiya BD, Ottemann BM, Thomas MB, et al. Neurotheranostics as personalized medicines. Adv Drug Deliv Rev. 2019;148:252–289. doi:10.1016/j.addr.2018.10.01130421721
   PubMed Web of Science ®Google Scholar
• Ross C, Taylor M, Fullwood N, Allsop D. Liposome delivery systems for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2018;13:8507–8522. doi:10.2147/IJN.S18311730587974
   PubMed Web of Science ®Google Scholar
• Wong KH, Riaz MK, Xie Y, et al. Review of current strategies for delivering Alzheimer’s Disease drugs across the blood-brain barrier. Int J Mol Sci. 2019;20:2. doi:10.3390/ijms20020381
   Web of Science ®Google Scholar
• Dong X. Current Strategies for Brain Drug Delivery. Theranostics. 2018;8(6):1481–1493. doi:10.7150/thno.2125429556336
   PubMed Web of Science ®Google Scholar
• Tosi G, Pederzoli F, Belletti D, et al. Nanomedicine in Alzheimer’s disease: amyloid beta targeting strategy. Prog Brain Res. 2019;245:57–88.30961872
   PubMed Web of Science ®Google Scholar
• Stanfield CL, Germann WJ. Il Sistema Nervoso; il Sistema nervoso Centrale [The Nervous System; the Central Nervous System]. In: Molinari CG, Marini HR, editors. Fisiologia Terza Edizione. [Physiology Third Edition]. Naples, Italy: EdiSES Srl; 2009:216–251. Italian.
   Google Scholar
• Freeman T. Focused ultrasound opens the blood-brain barrier. Physics World Available from: https://physicsworld.com/a/focused-ultrasound-opens-the-blood-brain-barrier-2/. Accessed 8 4, 2020.
   Google Scholar
• Vasile C. Chapter 1 Polymeric Nanomaterials: Recent Developments, Properties and Medical Applications in Polymeric Nanomaterials in Nanotherapeutics. Elsevier; 2019.
   Google Scholar
• Puri A, Loomis K, Smith B, et al. Lipid-based nanoparticles as pharmaceutical drug carriers: from concepts to clinic. Crit Rev Ther Drug Carrier Syst. 2009;26(6):523–580. doi:10.1615/CritRevTherDrugCarrierSyst.v26.i6.1020402623
   PubMed Web of Science ®Google Scholar
• Pandey P, Dahiya M. A brief review on inorganic nanoparticles. J Critical Rev. 2016;3:18–26.
   Google Scholar
• Anzar N, Hasan R, Tyagi M, Yadav N, Narang J. Carbon Nanotube - a Review on Synthesis, Properties and Plethora of Applications in the Field of Biomedical Science. 1 Sensors International; 2020.
   Google Scholar
• Bhattacharya S, Prajapati B, Paul A. A conceptual review on micro bubbles. Biomed J Sci & Tech Res. 2017.
   Google Scholar
• Le TC, Zhai J, Chiu WH, Tran PA, Tran N. Janus particles: recent advances in the biomedical applications. Int J Nanomedicine. 2019;14:6749–6777. doi:10.2147/IJN.S16903031692550
   PubMed Web of Science ®Google Scholar
• Praça C, Rai A, Santos T, et al. A nanoformulation for the preferential accumulation in adult neurogenic niches. J Control Release. 2018;284:57–72. doi:10.1016/j.jconrel.2018.06.01329902485
   PubMed Web of Science ®Google Scholar
• Agrawal M, Ajazuddin TDK, et al. Recent advancements in liposomes targeting strategies to cross blood-brain barrier (BBB) for the treatment of Alzheimer’s disease. J Control Release. 2017;260:61–77. doi:10.1016/j.jconrel.2017.05.01928549949
   PubMed Web of Science ®Google Scholar
• Niu X, Chen J, Gao J. Nanocarriers as a powerful vehicle to overcome blood-brain barrier in treating neurodegenerative diseases: focus on recent advances. Asian J Pharm Sci. 2019;14(5):480–496. doi:10.1016/j.ajps.2018.09.00532104476
   PubMed Web of Science ®Google Scholar
• Teixeira MI, Lopes CM, Amaral MH, Costa PC. Current insights on lipid nanocarrier-assisted drug delivery in the treatment of neurodegenerative diseases. Eur J Pharm Biopharm. 2020;149:192–217. doi:10.1016/j.ejpb.2020.01.00531982574
   PubMed Web of Science ®Google Scholar
• Gao H. Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B. 2016;6(4):268–286. doi:10.1016/j.apsb.2016.05.01327471668
   PubMed Web of Science ®Google Scholar
• Pardridge WM. Re-engineering therapeutic antibodies for Alzheimer’s disease as blood-brain barrier penetrating bi-specific antibodies. Expert Opin Biol Ther. 2016;16(12):1455–1468. doi:10.1080/14712598.2016.123019527572805
   PubMed Web of Science ®Google Scholar
• Arora S, Sharma D, Singh J. GLUT-1: an effective target to deliver brain-derived neurotrophic factor gene across the blood brain barrier. ACS Chem Neurosci. 2020;11:1620–1633. doi:10.1021/acschemneuro.0c0007632352752
   PubMed Web of Science ®Google Scholar
• Betzer O, Shilo M, Motiei M, Popovtzer R. Insulin-Coated Gold Nanoparticles as an Effective Approach for Bypassing the Blood-Brain Barrier.Proc. SPIE 10891, Nanoscale Imaging, Sensing, and Actuation for Biomedical Applications XVI, 108911H. 2019. doi:10.1117/12.2510353
   Google Scholar
• Majerova P, Hanes J, Olesova D, Sinsky J, Pilipcinec E, Kovac A. Novel blood-brain barrier shuttle peptides discovered through the phage display method. Molecules. 2020;25:4. doi:10.3390/molecules25040874
   Web of Science ®Google Scholar
• McCully M, Sanchez-Navarro M, Teixido M, Giralt E. Peptide mediated brain delivery of nano- and submicroparticles: a synergistic approach. Curr Pharm Des. 2018;24(13):1366–1376. doi:10.2174/138161282466617120111512629205110
   PubMed Web of Science ®Google Scholar
• Guo Q, Xu S, Yang P, et al. A dual-ligand fusion peptide improves the brain-neuron targeting of nanocarriers in Alzheimer’s disease mice. J Control Release. 2020;320:347–362. doi:10.1016/j.jconrel.2020.01.03931978446
   PubMed Web of Science ®Google Scholar
• Formicola B, Cox A, Dal Magro R, Masserini M, Re F. Nanomedicine for the treatment of Alzheimer’s Disease. J Biomed Nanotechnol. 2019;15(10):1997–2024. doi:10.1166/jbn.2019.283731462368
   PubMed Web of Science ®Google Scholar
• Crowe TP, Greenlee MHW, Kanthasamy AG, Hsu WH. Mechanism of intranasal drug delivery directly to the brain. Life Sci. 2018;195:44–52. doi:10.1016/j.lfs.2017.12.02529277310
   PubMed Web of Science ®Google Scholar
• Akel H, Ismail R, Csóka I. Progress and perspectives of brain-targeting lipid-based nanosystems via the nasal route in Alzheimer’s disease. Eur J Pharm Biopharm. 2020;148:38–53. doi:10.1016/j.ejpb.2019.12.01431926222
   PubMed Web of Science ®Google Scholar
• Samaridou E, Alonso MJ. Nose-to-brain peptide delivery - The potential of nanotechnology. Bioorg Med Chem. 2018;26(10):2888–2905. doi:10.1016/j.bmc.2017.11.00129170026
   PubMed Web of Science ®Google Scholar
• Gao X, Wu B, Zhang Q, et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release. 2007;121(3):156–167. doi:10.1016/j.jconrel.2007.05.02617628165
   PubMed Web of Science ®Google Scholar
• Agrawal M, Saraf S, Antimisiaris SG, Chougule MB, Shoyele SA, Alexander A. Nose-to-brain drug delivery: an update on clinical challenges and progress towards approval of anti-Alzheimer drugs. J Control Release. 2018;281:139–177. doi:10.1016/j.jconrel.2018.05.01129772289
   PubMed Web of Science ®Google Scholar
• Nanaki SG, Spyrou K, Bekiari C, et al. Hierarchical porous carbon-PLLA and PLGA hybrid nanoparticles for intranasal delivery of galantamine for Alzheimer’s Disease therapy. Pharmaceutics. 2020;12:3. doi:10.3390/pharmaceutics12030227
   Web of Science ®Google Scholar
• Adnet T, Groo AC, Picard C, et al. Pharmacotechnical development of a nasal drug delivery composite nanosystem intended for Alzheimer’s Disease treatment. Pharmaceutics. 2020;12:3. doi:10.3390/pharmaceutics12030251
   Web of Science ®Google Scholar
• Kamei N, Takeda-Morishita M. Brain delivery of insulin boosted by intranasal coadministration with cell-penetrating peptides. J Control Release. 2015;197:105–110. doi:10.1016/j.jconrel.2014.11.00425445695
   PubMed Web of Science ®Google Scholar
• Liu Y, Gong Y, Xie W, et al. Microbubbles in combination with focused ultrasound for the delivery of quercetin-modified sulfur nanoparticles through the blood brain barrier into the brain parenchyma and relief of endoplasmic reticulum stress to treat Alzheimer’s disease. Nanoscale. 2020;12(11):6498–6511. doi:10.1039/C9NR09713A32154811
   PubMed Web of Science ®Google Scholar
• Chen W, Ouyang J, Yi X, et al. Black phosphorus nanosheets as a neuroprotective nanomedicine for neurodegenerative disorder therapy. Adv Mater. 2018;30:3.
   Web of Science ®Google Scholar
• Zhou H, Gong Y, Liu Y, et al. Intelligently thermoresponsive flower-like hollow nano-ruthenium system for sustained release of nerve growth factor to inhibit hyperphosphorylation of tau and neuronal damage for the treatment of Alzheimer’s disease. Biomaterials. 2020;237:119822. doi:10.1016/j.biomaterials.2020.11982232035322
   PubMed Web of Science ®Google Scholar
• Liu W, Wang W, Dong X, Sun Y. Near-infrared light-powered janus nanomotor significantly facilitates inhibition of amyloid-β fibrillogenesis. ACS Appl Mater Interfaces. 2020;12(11):12618–12628. doi:10.1021/acsami.0c0234232105446
   PubMed Web of Science ®Google Scholar
• Carradori D, Balducci C, Re F, et al. Antibody-functionalized polymer nanoparticle leading to memory recovery in Alzheimer’s disease-like transgenic mouse model. Nanomedicine. 2018;14(2):609–618. doi:10.1016/j.nano.2017.12.00629248676
   PubMed Web of Science ®Google Scholar
• Luo Q, Lin YX, Yang PP, et al. A self-destructive nanosweeper that captures and clears amyloid β-peptides. Nat Commun. 2018;9(1):1802. doi:10.1038/s41467-018-04255-z29728565
   PubMedGoogle Scholar
• Zhang W, Christofferson AJ, Besford QA, et al. Metal-dependent inhibition of amyloid fibril formation: synergistic effects of cobalt-tannic acid networks. Nanoscale. 2019;11(4):1921–1928. doi:10.1039/C8NR09221D30644497
   PubMed Web of Science ®Google Scholar
• Sun J, Xie W, Zhu X, Xu M, Liu J. Sulfur nanoparticles with novel morphologies coupled with brain-targeting peptides RVG as a new type of inhibitor against metal-induced aβ aggregation. ACS Chem Neurosci. 2018;9(4):749–761. doi:10.1021/acschemneuro.7b0031229192759
   PubMed Web of Science ®Google Scholar
• Chung YJ, Lee BI, Park CB. Multifunctional carbon dots as a therapeutic nanoagent for modulating Cu(ii)-mediated β-amyloid aggregation. Nanoscale. 2019;11(13):6297–6306. doi:10.1039/C9NR00473D30882825
   PubMed Web of Science ®Google Scholar
• Liu H, Dong X, Liu F, Zheng J, Sun Y. Iminodiacetic acid-conjugated nanoparticles as a bifunctional modulator against Zn. J Colloid Interface Sci. 2017;505:973–982. doi:10.1016/j.jcis.2017.06.09328693098
   PubMed Web of Science ®Google Scholar
• Sun D, Zhang W, Yu Q, et al. Chiral penicillamine-modified selenium nanoparticles enantioselectively inhibit metal-induced amyloid β aggregation for treating Alzheimer’s disease. J Colloid Interface Sci. 2017;505:1001–1010. doi:10.1016/j.jcis.2017.06.08328693096
   PubMed Web of Science ®Google Scholar
• Zhang X, Zhong M, Zhao P, et al. Screening a specific Zn(ii)-binding peptide for improving the cognitive decline of Alzheimer’s disease in APP/PS1 transgenic mice by inhibiting Zn. Biomater Sci. 2019;7(12):5197–5210. doi:10.1039/C9BM00676A31588929
   PubMed Web of Science ®Google Scholar
• Han Q, Wang X, Liu X, et al. MoO3-X nanodots with dual enzyme mimic activities as multifunctional modulators for amyloid assembly and neurotoxicity. J Colloid Interface Sci. 2019;539:575–584. doi:10.1016/j.jcis.2018.12.09330611053
   PubMed Web of Science ®Google Scholar
• Zhang Z, Wang J, Song Y, Wang Z, Dong M, Liu L. Disassembly of Alzheimer’s amyloid fibrils by functional upconversion nanoparticles under near-infrared light irradiation. Colloids Surf B Biointerfaces. 2019;181:341–348. doi:10.1016/j.colsurfb.2019.05.05331158696
   PubMed Web of Science ®Google Scholar
• Pederzoli F, Ruozi B, Duskey J, et al. Nanomedicine against Aβ aggregation by β-sheet breaker peptide delivery: in vitro evidence. Pharmaceutics. 2019;11:11. doi:10.3390/pharmaceutics11110572
   PubMed Web of Science ®Google Scholar
• Zhang H, Hao C, Qu A, et al. Light-induced chiral iron copper selenide nanoparticles prevent β-Amyloidopathy in vivo. Angew Chem Int Ed Engl. 2020.
   Web of Science ®Google Scholar
• Boonruamkaew P, Chonpathompikunlert P, Vong LB, et al. Chronic treatment with a smart antioxidative nanoparticle for inhibition of amyloid plaque propagation in Tg2576 mouse model of Alzheimer’s disease. Sci Rep. 2017;7(1):3785. doi:10.1038/s41598-017-03411-728630497
   PubMedGoogle Scholar
• Jeon SG, Cha MY, Kim JI, et al. Vitamin D-binding protein-loaded PLGA nanoparticles suppress Alzheimer’s disease-related pathology in 5XFAD mice. Nanomedicine. 2019;17:297–307. doi:10.1016/j.nano.2019.02.00430794963
   PubMed Web of Science ®Google Scholar
• Vakilinezhad MA, Amini A, Akbari Javar H, Baha’addini Beigi Zarandi BF, Montaseri H, Dinarvand R. Nicotinamide loaded functionalized solid lipid nanoparticles improves cognition in Alzheimer’s disease animal model by reducing Tau hyperphosphorylation. Daru. 2018;26(2):165–177. doi:10.1007/s40199-018-0221-530386982
   PubMed Web of Science ®Google Scholar
• Sonawane SK, Ahmad A, Chinnathambi S. Protein-capped metal nanoparticles inhibit tau aggregation in Alzheimer’s Disease. ACS Omega. 2019;4(7):12833–12840. doi:10.1021/acsomega.9b0141131460408
   PubMed Web of Science ®Google Scholar
• Cai X, Zhang K, Xie X, et al. Self-assembly hollow manganese Prussian white nanocapsules attenuate Tau-related neuropathology and cognitive decline. Biomaterials. 2020;231:119678. doi:10.1016/j.biomaterials.2019.11967831864019
   PubMed Web of Science ®Google Scholar
• Ji D, Wu X, Li D, et al. Protective effects of chondroitin sulphate nano-selenium on a mouse model of Alzheimer’s disease. Int J Biol Macromol. 2020;154:233–245. doi:10.1016/j.ijbiomac.2020.03.07932171837
   PubMed Web of Science ®Google Scholar
• Gao F, Zhao J, Liu P, et al. Preparation and in vitro evaluation of multi-target-directed selenium-chondroitin sulfate nanoparticles in protecting against the Alzheimer’s disease. Int J Biol Macromol. 2020;142:265–276. doi:10.1016/j.ijbiomac.2019.09.09831593732
   PubMed Web of Science ®Google Scholar
• Sierra C. Hypertension and the Risk of Dementia. Front Cardiovasc Med. 2020;7:5. doi:10.3389/fcvm.2020.0000532083095
   PubMed Web of Science ®Google Scholar
• Wahidi N, Lerner AJ. Blood pressure control and protection of the aging Brain. Neurotherapeutics. 2019;16(3):569–579. doi:10.1007/s13311-019-00747-y31161491
   PubMed Web of Science ®Google Scholar
• Novotny M, Klimova B, Valis M. Nitrendipine and dementia: forgotten positive facts? Front Aging Neurosci. 2018;10:418. doi:10.3389/fnagi.2018.0041830618724
   PubMed Web of Science ®Google Scholar
• Nimmrich V, Eckert A. Calcium channel blockers and dementia. Br J Pharmacol. 2013;169(6):1203–1210. doi:10.1111/bph.1224023638877
   PubMed Web of Science ®Google Scholar
• Alawdi SH, Eidi H, Safar MM, Abdel-Wahhab MA. Loading amlodipine on diamond nanoparticles: a novel drug delivery system. Nanotechnol Sci Appl. 2019;12:47–53. doi:10.2147/NSA.S23251732099339
   PubMed Web of Science ®Google Scholar
• Li T, Liang W, Xiao X, Qian Y. Nanotechnology, an alternative with promising prospects and advantages for the treatment of cardiovascular diseases. Int J Nanomedicine. 2018;13:7349–7362. doi:10.2147/IJN.S17967830519019
   PubMed Web of Science ®Google Scholar
• Evans CW, Viola HM, Ho D, et al. Nanoparticle-mediated internalisation and release of a calcium channel blocker. RSC Adv. 2012;2(23):8587–8590. doi:10.1039/c2ra21058d
   Web of Science ®Google Scholar
• Jana U, Mohanty AK, Pal SL, Manna PK, Mohanta GP. Felodipine loaded PLGA nanoparticles: preparation, physicochemical characterization and in vivo toxicity study. Nano Convergence. 2014;1(1):31. doi:10.1186/s40580-014-0031-5
   Google Scholar
• Jana U, Mohanty AK, Manna PK, Mohanta GP. Preparation and characterization of nebivolol nanoparticles using Eudragit® RS100. Colloids Surf B Biointerfaces. 2014;113:269–275. doi:10.1016/j.colsurfb.2013.09.00124140793
   PubMed Web of Science ®Google Scholar
• Tóth OM, Menyhárt Á, Varga V, et al. Chitosan nanoparticles release nimodipine in response to tissue acidosis to attenuate spreading depolarization evoked during forebrain ischemia. Neuropharmacology. 2020;162:107850. doi:10.1016/j.neuropharm.2019.10785031715193
   PubMed Web of Science ®Google Scholar
• Wójtowicz S, Strosznajder AK, Jeżyna M, Strosznajder JB. The novel role of PPAR alpha in the brain: promising target in therapy of Alzheimer’s Disease and other neurodegenerative disorders. Neurochem Res. 2020;45:972–988. doi:10.1007/s11064-020-02993-532170673
   PubMed Web of Science ®Google Scholar
• Silva-Abreu M, Calpena AC, Andrés-Benito P, et al. PPARγ agonist-loaded PLGA-PEG nanocarriers as a potential treatment for Alzheimer’s disease: in vitro and in vivo studies. Int J Nanomedicine. 2018;13:5577–5590. doi:10.2147/IJN.S17149030271148
   PubMed Web of Science ®Google Scholar
• Xiao Y, Zhang E, Fu A. Promotion of SH-SY5Y cell growth by gold nanoparticles modified with 6-mercaptopurine and a neuron-penetrating peptide. Nanoscale Res Lett. 2017;12(1):641. doi:10.1186/s11671-017-2417-x29288282
   PubMedGoogle Scholar
• Marcus M, Smith A, Maswadeh A, et al. Magnetic targeting of growth factors using iron oxide nanoparticles. Nanomaterials. 2018;8:9. doi:10.3390/nano8090707
   Web of Science ®Google Scholar
• Yuan M, Wang Y, Qin YX. Engineered nanomedicine for neuroregeneration: light emitting diode-mediated superparamagnetic iron oxide-gold core-shell nanoparticles functionalized by nerve growth factor. Nanomedicine. 2019;21:102052. doi:10.1016/j.nano.2019.10205231349088
   PubMed Web of Science ®Google Scholar
• Yuan M, Wang Y, Qin YX. Promoting neuroregeneration by applying dynamic magnetic fields to a novel nanomedicine: superparamagnetic iron oxide (SPIO)-gold nanoparticles bounded with nerve growth factor (NGF). Nanomedicine. 2018;14(4):1337–1347. doi:10.1016/j.nano.2018.03.00429627520
   PubMed Web of Science ®Google Scholar
• Katebi S, Esmaeili A, Ghaedi K, Zarrabi A. Superparamagnetic iron oxide nanoparticles combined with NGF and quercetin promote neuronal branching morphogenesis of PC12 cells. Int J Nanomedicine. 2019;14:2157–2169. doi:10.2147/IJN.S19187830992663
   PubMed Web of Science ®Google Scholar
• Kalra EK. Nutraceutical–definition and introduction. AAPS PharmSci. 2003;5(3):E25. doi:10.1208/ps05032514621960
   PubMedGoogle Scholar
• Kanubaddi KR, Yang SH, Wu LW, Lee CH, Weng CF. Nanoparticle-conjugated nutraceuticals exert prospectively palliative of amyloid aggregation. Int J Nanomedicine. 2018;13:8473–8485. doi:10.2147/IJN.S17948430587972
   PubMed Web of Science ®Google Scholar
• Pinheiro RGR, Granja A, Loureiro JA, et al. Quercetin lipid nanoparticles functionalized with transferrin for Alzheimer’s disease. Eur J Pharm Sci. 2020;148:105314. doi:10.1016/j.ejps.2020.10531432200044
   PubMed Web of Science ®Google Scholar
• Sun D, Li N, Zhang W, et al. Design of PLGA-functionalized quercetin nanoparticles for potential use in Alzheimer’s disease. Colloids Surf B Biointerfaces. 2016;148:116–129. doi:10.1016/j.colsurfb.2016.08.05227591943
   PubMed Web of Science ®Google Scholar
• Amin FU, Shah SA, Badshah H, Khan M, Kim MO. Anthocyanins encapsulated by PLGA@PEG nanoparticles potentially improved its free radical scavenging capabilities via p38/JNK pathway against Aβ. J Nanobiotechnol. 2017;15(1):12. doi:10.1186/s12951-016-0227-4
   PubMedGoogle Scholar
• Ishak RAH, Mostafa NM, Kamel AO. Stealth lipid polymer hybrid nanoparticles loaded with rutin for effective brain delivery comparative study with the gold standard (Tween 80): optimization, characterization and biodistribution. Drug Deliv. 2017;24(1):1874–1890. doi:10.1080/10717544.2017.141026329191047
   PubMed Web of Science ®Google Scholar
• Ali T, Kim MJ, Rehman SU, Ahmad A, Kim MO. Anthocyanin-loaded PEG-gold nanoparticles enhanced the neuroprotection of anthocyanins in an Aβ. Mol Neurobiol. 2017;54(8):6490–6506. doi:10.1007/s12035-016-0136-427730512
   PubMed Web of Science ®Google Scholar
• Kim MJ, Rehman SU, Amin FU, Kim MO. Enhanced neuroprotection of anthocyanin-loaded PEG-gold nanoparticles against Aβ. Nanomedicine. 2017;13(8):2533–2544. doi:10.1016/j.nano.2017.06.02228736294
   PubMed Web of Science ®Google Scholar
• Kheradmand E, Hajizadeh Moghaddam A, Zare M. Neuroprotective effect of hesperetin and nano-hesperetin on recognition memory impairment and the elevated oxygen stress in rat model of Alzheimer’s disease. Biomed Pharmacother. 2018;97:1096–1101. doi:10.1016/j.biopha.2017.11.04729136946
   PubMed Web of Science ®Google Scholar
• Wijiani N, Isadiartuti D, Rijal MAS, Yusuf H. Characterization and dissolution study of micellar curcumin-spray dried powder for oral delivery. Int J Nanomedicine. 2020;15:1787–1796. doi:10.2147/IJN.S24505032214811
   PubMed Web of Science ®Google Scholar
• Chen S, Han Y, Sun C, et al. Effect of molecular weight of hyaluronan on zein-based nanoparticles: fabrication, structural characterization and delivery of curcumin. Carbohydr Polym. 2018;201:599–607. doi:10.1016/j.carbpol.2018.08.11630241858
   PubMed Web of Science ®Google Scholar
• Lohan S, Raza K, Mehta SK, Bhatti GK, Saini S, Singh B. Anti-Alzheimer’s potential of berberine using surface decorated multi-walled carbon nanotubes: A preclinical evidence. Int J Pharm. 2017;530(12):263–278. doi:10.1016/j.ijpharm.2017.07.08028774853
   PubMedGoogle Scholar
• Sathya S, Shanmuganathan B, Devi KP. Deciphering the anti-apoptotic potential of α-bisabolol loaded solid lipid nanoparticles against Aβ induced neurotoxicity in Neuro-2a cells. Colloids Surf B Biointerfaces. 2020;190:110948. doi:10.1016/j.colsurfb.2020.11094832160583
   PubMed Web of Science ®Google Scholar
• Brenza TM, Ghaisas S, Ramirez JEV, et al. Neuronal protection against oxidative insult by polyanhydride nanoparticle-based mitochondria-targeted antioxidant therapy. Nanomedicine. 2017;13(3):809–820. doi:10.1016/j.nano.2016.10.00427771430
   PubMed Web of Science ®Google Scholar
• Aalinkeel R, Kutscher HL, Singh A, et al. Neuroprotective effects of a biodegradable poly(lactic-co-glycolic acid)-ginsenoside Rg3 nanoformulation: a potential nanotherapy for Alzheimer’s disease? J Drug Target. 2018;26(2):182–193. doi:10.1080/1061186X.2017.135400228697660
   PubMed Web of Science ®Google Scholar
• Sathya S, Shanmuganathan B, Saranya S, Vaidevi S, Ruckmani K, Pandima Devi K. Phytol-loaded PLGA nanoparticle as a modulator of Alzheimer’s toxic Aβ peptide aggregation and fibrillation associated with impaired neuronal cell function.. Artif Cells Nanomed Biotechnol. 2018;46(8):1719–1730. doi:10.1080/21691401.2017.139182229069924
   PubMed Web of Science ®Google Scholar
• Cano A, Ettcheto M, Chang JH, et al. Dual-drug loaded nanoparticles of Epigallocatechin-3-gallate (EGCG)/Ascorbic acid enhance therapeutic efficacy of EGCG in a APPswe/PS1dE9 Alzheimer’s disease mice model. J Control Release. 2019;301:62–75. doi:10.1016/j.jconrel.2019.03.01030876953
   PubMed Web of Science ®Google Scholar
• Xu R, Wang J, Xu J, et al. Rhynchophylline Loaded-mPEG-PLGA nanoparticles coated with tween-80 for preliminary study in Alzheimer’s Disease. Int J Nanomedicine. 2020;15:1149–1160. doi:10.2147/IJN.S23692232110013
   PubMed Web of Science ®Google Scholar
• Chen S, Han Y, Huang J, et al. Fabrication and characterization of layer-by-layer composite nanoparticles based on zein and hyaluronic acid for codelivery of Curcumin and Quercetagetin. ACS Appl Mater Interfaces. 2019;11(18):16922–16933. doi:10.1021/acsami.9b0252930985111
   PubMed Web of Science ®Google Scholar
• Okuda M, Fujita Y, Sugimoto H. The additive effects of low dose intake of ferulic acid, phosphatidylserine and curcumin, not alone, improve cognitive function in APPswe/PS1dE9 transgenic mice. Biol Pharm Bull. 2019;42(10):1694–1706. doi:10.1248/bpb.b19-0033231582657
   PubMed Web of Science ®Google Scholar
• Agarwal H, Shanmugam V. A review on anti-inflammatory activity of green synthesized zinc oxide nanoparticle: mechanism-based approach. Bioorg Chem. 2020;94:103423. doi:10.1016/j.bioorg.2019.10342331776035
   PubMed Web of Science ®Google Scholar
• Badeggi UM, Ismail E, Adeloye AO, et al. Green synthesis of gold nanoparticles capped with procyanidins from. Biomolecules. 2020;10:3. doi:10.3390/biom10030452
   Web of Science ®Google Scholar
• Lee YJ, Park Y. Green synthetic nanoarchitectonics of gold and silver nanoparticles prepared using quercetin and their cytotoxicity and catalytic applications. J Nanosci Nanotechnol. 2020;20(5):2781–2790. doi:10.1166/jnn.2020.1745331635614
   PubMed Web of Science ®Google Scholar
• Youssif KA, Haggag EG, Elshamy AM, et al. Anti-Alzheimer potential, metabolomic profiling and molecular docking of green synthesized silver nanoparticles of Lampranthus coccineus and Malephora lutea aqueous extracts. PLoS One. 2019;14(11):e0223781. doi:10.1371/journal.pone.022378131693694
   PubMed Web of Science ®Google Scholar
• Dos Santos Rodrigues B, Kanekiyo T, Singh J. ApoE-2 brain-targeted gene therapy through transferrin and penetratin tagged liposomal nanoparticles. Pharm Res. 2019;36(11):161. doi:10.1007/s11095-019-2691-731529284
   PubMed Web of Science ®Google Scholar
• Rassu G, Soddu E, Posadino AM, et al. Nose-to-brain delivery of BACE1 siRNA loaded in solid lipid nanoparticles for Alzheimer’s therapy. Colloids Surf B Biointerfaces. 2017;152:296–301. doi:10.1016/j.colsurfb.2017.01.03128126681
   PubMed Web of Science ®Google Scholar
• Wang P, Zheng X, Guo Q, et al. Systemic delivery of BACE1 siRNA through neuron-targeted nanocomplexes for treatment of Alzheimer’s disease. J Control Release. 2018;279:220–233. doi:10.1016/j.jconrel.2018.04.03429679667
   PubMed Web of Science ®Google Scholar
• Poplawski SG, Garbett KA, McMahan RL, et al. An antisense oligonucleotide leads to suppressed transcription of hdac2 and long-term memory enhancement. Mol Ther Nucleic Acids. 2020;19:1399–1412. doi:10.1016/j.omtn.2020.01.02732160709
   PubMedGoogle Scholar
• Shao X, Cui W, Xie X, Ma W, Zhan Y, Lin Y. Treatment of Alzheimer’s disease with framework nucleic acids. Cell Prolif. 2020;e12787.32162733
   PubMed Web of Science ®Google Scholar
• Zhang FQ, Jiang JL, Zhang JT, Niu H, Fu XQ, Zeng LL. Current status and future prospects of stem cell therapy in Alzheimer’s disease. Neural Regen Res. 2020;15(2):242–250. doi:10.4103/1673-5374.26554431552889
   PubMed Web of Science ®Google Scholar
• Reddy AP, Ravichandran J, Carkaci-Salli N. Neural regeneration therapies for Alzheimer’s and Parkinson’s disease-related disorders. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165506. doi:10.1016/j.bbadis.2019.06.02031276770
   PubMed Web of Science ®Google Scholar
• Zhang L, Dong ZF, Zhang JY. Immunomodulatory role of mesenchymal stem cells in Alzheimer’s disease. Life Sci. 2020;246:117405. doi:10.1016/j.lfs.2020.11740532035129
   PubMed Web of Science ®Google Scholar
• Hour FQ, Moghadam AJ, Shakeri-Zadeh A, Bakhtiyari M, Shabani R, Mehdizadeh M. Magnetic targeted delivery of the SPIONs-labeled mesenchymal stem cells derived from human Wharton’s jelly in Alzheimer’s rat models. J Control Release. 2020;321:430–441. doi:10.1016/j.jconrel.2020.02.03532097673
   PubMed Web of Science ®Google Scholar
• Sato M, Takizawa H, Nakamura A, Turner BJ, Shabanpoor F, Aoki Y. Application of urine-derived stem cells to cellular modeling in neuromuscular and neurodegenerative diseases. Front Mol Neurosci. 2019;12:297. doi:10.3389/fnmol.2019.0029731920531
   PubMed Web of Science ®Google Scholar
• Mungenast AE, Siegert S, Tsai LH. Modeling Alzheimer’s disease with human induced pluripotent stem (iPS) cells. Mol Cell Neurosci. 2016;73:13–31. doi:10.1016/j.mcn.2015.11.01026657644
   PubMed Web of Science ®Google Scholar
• Chang KH, Lee-Chen GJ, Huang CC, et al. Modeling Alzheimer’s Disease by induced pluripotent stem cells carrying APP D678H mutation. Mol Neurobiol. 2019;56(6):3972–3983. doi:10.1007/s12035-018-1336-x30238389
   PubMed Web of Science ®Google Scholar
• Zhang X, Hu D, Shang Y, Qi X. Using induced pluripotent stem cell neuronal models to study neurodegenerative diseases. Biochim Biophys Acta Mol Basis Dis. 2020;1866(4):165431. doi:10.1016/j.bbadis.2019.03.00430898538
   PubMed Web of Science ®Google Scholar
• Hossini AM, Megges M, Prigione A, et al. Induced pluripotent stem cell-derived neuronal cells from a sporadic Alzheimer’s disease donor as a model for investigating AD-associated gene regulatory networks. BMC Genomics. 2015;16:84. doi:10.1186/s12864-015-1262-525765079
   PubMed Web of Science ®Google Scholar
• Pavoni S, Jarray R, Nassor F, et al. Small-molecule induction of Aβ-42 peptide production in human cerebral organoids to model Alzheimer’s disease associated phenotypes. PLoS One. 2018;13(12):e0209150. doi:10.1371/journal.pone.020915030557391
   PubMed Web of Science ®Google Scholar
• Raja WK, Mungenast AE, Lin YT, et al. Self-Organizing 3D human neural tissue derived from induced pluripotent stem cells recapitulate Alzheimer’s Disease phenotypes. PLoS One. 2016;11(9):e0161969. doi:10.1371/journal.pone.016196927622770
   PubMed Web of Science ®Google Scholar
• Nassor F, Jarray R, Biard DSF, et al. Long term gene expression in human induced pluripotent stem cells and cerebral organoids to model a Neurodegenerative Disease. Front Cell Neurosci. 2020;14:14. doi:10.3389/fncel.2020.0001432116560
   PubMed Web of Science ®Google Scholar
• Aulić S, Bolognesi ML, Legname G. Small-molecule theranostic probes: a promising future in neurodegenerative diseases. Int J Cell Biol. 2013;2013:150952. doi:10.1155/2013/15095224324497
   PubMedGoogle Scholar
• Chakravarthy M, Chen S, Dodd PR, Veedu RN. Nucleic acid-based theranostics for tackling Alzheimer’s Disease. Theranostics. 2017;7(16):3933–3947. doi:10.7150/thno.2152929109789
   PubMed Web of Science ®Google Scholar
• Papadia K, Markoutsa E, Mourtas S, et al. Multifunctional LUV liposomes decorated for BBB and amyloid targeting. A. In vitro proof-of-concept. Eur J Pharm Sci. 2017;101:140–148. doi:10.1016/j.ejps.2017.02.01928193538
   PubMed Web of Science ®Google Scholar
• Mourtas S, Christodoulou P, Klepetsanis P, Gatos D, Barlos K, Antimisiaris SG. Preparation of Benzothiazolyl-Decorated Nanoliposomes. Molecules. 2019;24:8. doi:10.3390/molecules24081540
   Web of Science ®Google Scholar
• Caldorera-Moore M, Guimard N, Shi L, Roy K. Designer nanoparticles: incorporating size, shape and triggered release into nanoscale drug carriers. Expert Opin Drug Deliv. 2010;7(4):479–495. doi:10.1517/1742524090357997120331355
   PubMed Web of Science ®Google Scholar
• Dal Magro R, Simonelli S, Cox A, et al. The extent of human apolipoprotein a-i lipidation strongly affects the β-amyloid efflux across the blood-brain barrier. Front Neurosci. 2019;13:419. doi:10.3389/fnins.2019.0041931156358
   PubMed Web of Science ®Google Scholar
• Binda A, Panariti A, Barbuti A, et al. Modulation of the intrinsic neuronal excitability by multifunctional liposomes tailored for the treatment of Alzheimer’s disease. Int J Nanomedicine. 2018;13:4059–4071. doi:10.2147/IJN.S16156330034232
   PubMed Web of Science ®Google Scholar
• Rodriguez Then FS, Jackson J, Ware C, Churchyard R, Hanseeuw B. Interdisciplinary and transdisciplinary perspectives: on the road to a holistic approach to dementia prevention and care. J Alzheimers Dis Rep. 2020;4(1):39–48. doi:10.3233/ADR-18007032206756
   PubMedGoogle Scholar